CDK4 and familial pancreatic carcinoma: One of the best characterized dependencies involves cell cycle regulation, potentially explaining why the combination of selective G12C inhibitors with CDK4/6 inhibitors presents a synergistic activity in preclinical models of pancreatic cancer and NSCLC [112,113].